Comparison of clinical characteristics between MPAL with T-lineage differentiation and MPAL without T-lineage differentiation
| . | MPAL with T-lineage differentiation (n = 15) . | MPAL without T-lineage differentiation (n = 14) . |
|---|---|---|
| Age, median (IQR), y | 43 (24.5-62.5) | 35.5 (11.2-55.8) |
| Sex, M/F | 10/5 | 8/6 |
| Prior history | 3* | 1† |
| Extramedullary disease‡ | 9 | 0 |
| BM involvement | 14 | 14 |
| CNS involvement | 5 | 3 |
| CBC at the diagnosis, median (IQR) | ||
| WBC, ×109/L | 4.1 (2.5-37.3) | 25 (14-106.5) |
| ANC, ×109/L | 0.6 (0.3-2.1) | 1.3 (0.6-1.6) |
| Hb, g/dL | 9.4 (8.1-12.8) | 8.9 (8.1-10.4) |
| PLT, ×109/L§ | 143 (49.5-242.5) | 81 (45.2-121.2) |
| Blasts, % | 27.5 (0-49.5) | 34 (24.2-78.6) |
| BM blasts, % | 75 (64.5-87) | 82 (73.8-90) |
| Abnormal karyotype | 9 | 12 |
| Induction regimens, AML/ALL | 4/11 | 2/12 |
| Achieving CR1 | 11 | 13 |
| Allo-HSCT | 9 | 11 |
| Pre-HSCT MRD positivity | 6 | 4 |
| . | MPAL with T-lineage differentiation (n = 15) . | MPAL without T-lineage differentiation (n = 14) . |
|---|---|---|
| Age, median (IQR), y | 43 (24.5-62.5) | 35.5 (11.2-55.8) |
| Sex, M/F | 10/5 | 8/6 |
| Prior history | 3* | 1† |
| Extramedullary disease‡ | 9 | 0 |
| BM involvement | 14 | 14 |
| CNS involvement | 5 | 3 |
| CBC at the diagnosis, median (IQR) | ||
| WBC, ×109/L | 4.1 (2.5-37.3) | 25 (14-106.5) |
| ANC, ×109/L | 0.6 (0.3-2.1) | 1.3 (0.6-1.6) |
| Hb, g/dL | 9.4 (8.1-12.8) | 8.9 (8.1-10.4) |
| PLT, ×109/L§ | 143 (49.5-242.5) | 81 (45.2-121.2) |
| Blasts, % | 27.5 (0-49.5) | 34 (24.2-78.6) |
| BM blasts, % | 75 (64.5-87) | 82 (73.8-90) |
| Abnormal karyotype | 9 | 12 |
| Induction regimens, AML/ALL | 4/11 | 2/12 |
| Achieving CR1 | 11 | 13 |
| Allo-HSCT | 9 | 11 |
| Pre-HSCT MRD positivity | 6 | 4 |
ANC, absolute neutrophil count; BM, bone marrow; CNS, central nervous system; Hb, hemoglobin; IQR, interquartile range; MRD, measurable residual disease; PLT, platelets; WBC, white blood cell count.
Classical Hodgkin lymphoma treated 8 years ago with ABVD (Adriamycin, bleomycin, vinblastine, and dacarbazine) and no evidence of disease (n = 1), stage I lung carcinoma 20 years ago treated with surgery and no evidence of disease (n = 1), HIV treated with highly active antiretroviral therapy (n = 1).
Melanoma treated with surgery, with no evidence of disease (n = 1).
Fisher’s exact test, P = .001; lymph nodes (n = 8) and skin (n = 1).
Student t test, P = .06.